SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (299)6/22/1999 2:34:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1475
 
I agree, but it's a big "if".

Still among my top three holdings, but I consider this to be an extreme-risk investment. AlloMune and 507/autoimmune seem to be going slowly, but I'm looking forward to the GvH presentation and associated commentary, if any.

Again, if you like to mix big science with huge markets, one can't beat BTRN for leverage. The trouble is, some good science doesn't effectively find it's way to the clinic until after a business plan dies. I'm keeping my head up.



To: LLCF who wrote (299)6/22/1999 2:56:00 PM
From: Pierre Borczuk  Read Replies (1) | Respond to of 1475
 
I will hunt the WSJ article down

Underground immunosupressants, meaning like unapproved herbs and concoctions? Are they telling their doctors? Seems like a lot to worry about keeping these patients healthy (rejection and infection ) , now have to add underground meds

Pierre


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News